News Lilly and Boehringer biosimilar undercuts Lantus by 15% Sanofi under pressure following long-awaited biosimilar launch.
News "I'm going to bring down drug prices" - Trump President-elect takes swipe at pharma after Time "Person of the Year" accolade.
News Cost the barrier, but Novo not giving up on insulin pill, sa... Cost of pill will be too much for payers to stomach, says Novo.
Views & Analysis The 'game changers' in diabetes: Novo and Lilly battle it ou... Two diabetes drugs, Lilly and Boehringer Ingelheim’s (BI) Jardiance and Novo Nordisk’s Victoza, have shown they can go beyond lowering blood sugar, and actually save lives and cut heart attacks
News Novo's next-gen diabetes drug could be best at cutting heart... Novo boosted by results from next-gen GLP-1.
News AI specialists Enveda and Basecamp rake in the cash AI-powered drug discovery companies Enveda and Basecamp have completed impressive funding rounds, worth $311m and $140m, respectively.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
